ICON Public Limited (NASDAQ:ICLR) Receives $304.27 Average PT from Analysts

Shares of ICON Public Limited (NASDAQ:ICLR) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $304.27.

ICLR has been the subject of a number of recent research reports. Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. TD Cowen dropped their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, JPMorgan Chase & Co. dropped their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, October 25th.

ICON Public Trading Down 5.2 %

Shares of NASDAQ:ICLR opened at $189.64 on Wednesday. The stock has a 50 day moving average of $267.03 and a 200 day moving average of $301.30. The company has a market cap of $15.64 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 1.51 and a beta of 1.25. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 12-month low of $188.57 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.10 earnings per share. As a group, equities research analysts expect that ICON Public will post 13.43 EPS for the current year.

Institutional Trading of ICON Public

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new stake in ICON Public during the 2nd quarter valued at $54,000. ORG Partners LLC bought a new position in ICON Public in the 2nd quarter valued at $59,000. GAMMA Investing LLC grew its position in ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in ICON Public by 119.6% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after acquiring an additional 226 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.